MODALIS THERAPEUTICS
Modalis Therapeutics Corporation is an biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo.
MODALIS THERAPEUTICS
Industry:
Biotechnology Health Care Life Science
Founded:
2016-01-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.modalistx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
38.55 M USD
Technology used in webpage:
Google Apps For Business GMO Internet DNS
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Protein Crystal
Protein Crystal is a bio-venture company that develops protein embedding technology.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Mizuho Capital
Mizuho Capital investment in Series B - Modalis Therapeutics
Shinsei Capital Partners
Shinsei Capital Partners investment in Series B - Modalis Therapeutics
Pegasus Tech Ventures
Pegasus Tech Ventures investment in Series B - Modalis Therapeutics
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Series B - Modalis Therapeutics
SBI Investment
SBI Investment investment in Series B - Modalis Therapeutics
SMBC Venture Capital
SMBC Venture Capital investment in Series B - Modalis Therapeutics
CareNet
CareNet investment in Series B - Modalis Therapeutics
UTokyo Innovation Platform
UTokyo Innovation Platform investment in Series B - Modalis Therapeutics
Akira Katayama
Akira Katayama investment in Series B - Modalis Therapeutics
Nippon Venture Capital
Nippon Venture Capital investment in Series A - Modalis Therapeutics
Official Site Inspections
http://www.modalistx.com
- Host name: 111.171.217.34
- IP address: 111.171.217.34
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "Modalis Therapeutics"
Modalis Therapeutics - Crunchbase Company Profile
Modalis is a biotech company that develops therapeutics using CRISPR based …See details»
Modalis Therapeutics - LinkedIn
Modalis Therapeutics | 4,212 followers on LinkedIn. Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology | Modalis Therapeutics Corporation …See details»
Message - Modalistx
Modalis is a biotechnology company with the objective of developing therapeutics through the use of pioneering technologies, including gene therapy and genome editing. Headquartered in …See details»
SOLVE FSHD and Modalis Announce Strategic ... - Montreal Gazette
Jun 8, 2025 SOLVE FSHD Alexandra Grant, House of Wilson [email protected] Modalis Therapeutics Corporation Corporate Planning Department [email protected] SOLVE …See details»
Contact | Modalis Therapeutics - Official Site
In response to the content of your inquiry 1）This page is protected by encryption technology (SSL). 2）Depending on the content of your inquiry, it may take some time for us to confirm …See details»
Modalis Therapeutics has received an Orphan Drug Designation …
Oct 25, 2024 For further information, please contact: Modalis Therapeutics Corporation Corporate Communications Sawako Nakamura [email protected]See details»
Contact | Modalis Therapeutics - Official Site
Select your inquiry 【Required】 Investor Media Pharmaceutical Company Academia Recruitment Others Name 【Required】 Organization Name Phone Number 【Required】 E …See details»
SOLVE FSHD and Modalis Announce Strategic ... - Financial Post
Jun 8, 2025 SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned …See details»
株式会社モダリス - Modalistx
株式会社モダリスのウェブサイト。私たちは、独自のゲノム編集プラットフォームCRISPR-GNDMで、遺伝子疾患に対する治療薬の開発を目指すバイ …See details»
SOLVE FSHD and Modalis Announce Strategic Collaboration to …
Jun 9, 2025 VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.-- (BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating …See details»
SOLVE FSHD and Modalis Announce Strategic Collaboration to
Jun 9, 2025 SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned …See details»
SOLVE FSHD and Modalis Announce Strategic Collaboration to …
Jun 8, 2025 About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD.See details»
SOLVE FSHD and Modalis Announce Strategic Collaboration to …
Jun 9, 2025 VANCOUVER, Canada & TOKYO, Japan & WALTHAM, MA, USA I June 09, 2025 I SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for …See details»
SOLVE FSHD and Modalis Announce Strategic Collaboration to …
Jun 8, 2025 SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics …See details»
Modalis has been selected as a finalist in the XPRIZE ... - BioSpace
May 13, 2025 The Wilson family has committed $100 million to kick-start funding into projects that support the organization’s mission to find a cure for FSHD by 2027. The goal of SOLVE …See details»
@modalistx | X
The latest posts from @modalistxSee details»
Modalis Therapeutics CEO and Key Executive Team - Craft.co
Modalis Therapeutics's Director is Hideki Takeda. Other executives include Miyuki Shimane, Board Member; Teruhisa Tajima, Board Member and 2 others. See the full leadership team at …See details»
Modalis Therapeutics | LinkedIn
Modalis Therapeutics | LinkedInのフォロワー数4,217人。Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology | Modalis Therapeutics …See details»
MDL 103 - AdisInsight
May 21, 2025 MDL 103 is a gene editing therapeutic being developed by Modalis Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressiveSee details»
SOLVE FSHD and Modalis Announce Strategic Collaboration to …
Jun 8, 2025 SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics …See details»